MentiNova, Inc. is developing an oral medication that could alleviate L-Dopa Induced Dyskinesia in patients with Parkinsons disease. MentiNovas strategy is to use a drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in Parkinsons disease patients.
MentiNova was co-founded by M. Maral Mouradian, William Dow Lovett Professor of Neurology and Director, Center for Neurodegenerative and Neuroimmunologic Diseases at Rutgers Biomedical and Health Sciences-Robert Wood Johnson Medical School.